Molassiotis A, Lopez-Nahas V, Chung W Y, Lam S W
University of Nottingham, School of Nursing, Floor A, Queen's Medical Centre, Nottingham NG7 2UH, UK.
AIDS Care. 2003 Feb;15(1):125-35. doi: 10.1080/0954012021000039833.
A pilot study was carried out in a group of six HIV-infected non-adherent men testing the effects of a behavioural medication management intervention on adherence with antiretroviral drugs. The study was prospective, using a one-group repeated-measures design. Adherence was measured using two self-reports. The intervention was a behaviourally-based programme that lasted for three months and included individualized education about antiretroviral medication and their side effects; positive reinforcement and encouragement; individualized counselling weekly; follow-up calls; and lifestyle assessment and the identification of adherence barriers. Assessments were carried out at recruitment, immediately after the initiation of the intervention, one month, three months and six months later. Results suggested that the intervention enhanced adherence rates from a mean percentage of 80.27 at baseline to a mean of 97.5% at the end of follow-up (six months time point). Similar improvement was observed in the scores of the scale measuring adherence difficulties. Further, CD4+ counts also slightly improved. Interviews with four of the participants at the end of the study highlighted the problems experienced by patients in taking their medication and supported the usefulness of the intervention. Because of the complexity of the factors behind adherence, it is important that patients are supported with individualized medication management programmes.
在一组六名感染艾滋病毒但未坚持服药的男性中开展了一项试点研究,以测试行为药物管理干预措施对抗逆转录病毒药物依从性的影响。该研究为前瞻性研究,采用单组重复测量设计。依从性通过两份自我报告进行测量。干预措施是一个基于行为的项目,持续三个月,包括关于抗逆转录病毒药物及其副作用的个性化教育;积极强化和鼓励;每周进行个性化咨询;随访电话;以及生活方式评估和依从性障碍识别。在招募时、干预开始后立即、干预开始后一个月、三个月和六个月进行评估。结果表明,干预措施使依从率从基线时的平均80.27%提高到随访结束时(六个月时间点)的平均97.5%。在测量依从性困难的量表得分方面也观察到了类似的改善。此外,CD4+细胞计数也略有改善。研究结束时对四名参与者的访谈突出了患者在服药过程中遇到的问题,并支持了该干预措施的有效性。由于依从性背后因素的复杂性,为患者提供个性化药物管理项目的支持非常重要。